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Rare variants have been shown to be significant contributors to complex disease risk. By 
definition, these variants have very low minor allele frequencies and traditional single-marker 
methods for statistical analysis are underpowered for typical sequencing study sample sizes. 
Multi-marker burden-type approaches attempt to identify aggregation of rare variants across case-
control status by analyzing relatively small partitions of the genome, such as genes. However, it is 
generally the case that the aggregative measure would be a mixture of causal and neutral variants, 
and these omnibus tests do not directly provide any indication of which rare variants may be 
driving a given association. Recently, Bayesian variable selection approaches have been proposed 
to identify rare variant associations from a large set of rare variants under consideration. While 
these approaches have been shown to be powerful at detecting associations at the rare variant level, 
there are often computational limitations on the total quantity of rare variants under consideration 
and compromises are necessary for large-scale application. Here, we propose a computationally 
efficient alternative formulation of this method using a probit regression approach specifically 
capable of simultaneously analyzing hundreds to thousands of rare variants. We evaluate our 
approach to detect causal variation on simulated data and examine sensitivity and specificity in 
instances of high rare variant dimensionality as well as apply it to pathway-level rare variant 
analysis results from a prostate cancer risk case-control sequencing study. Finally, we discuss 
potential extensions and future directions of this work.
Keywords
next-generation sequencing; MCMC; prostate cancer; burden testing
Introduction
With advancements in next-generation sequencing technologies, there has been a 
reinvigorated interest in the roles that rare variants (RVs) play in the genetic etiology of 
complex diseases [Cirulli and Goldstein 2010]. Due to low minor allele frequencies (MAFs), 
traditional single-variant risk association analysis methods on RVs suffer from low statistical 
power for even relatively large sample sizes, and specialized strategies are necessary to 
identify RV associations. This has led to the development of multi-marker aggregation 
strategies that are predicated on the notion that causal RVs may cluster in biologically 
relevant functional domains, such as genes [Bansal, et al. 2010]. There are a growing 
number of multi-marker omnibus methods available for RV association analysis that 
evaluate a priori defined target regions of interest (ROI) to localize clustering of causal RVs. 
These include various burden-based collapsing methods [Dering, et al. 2011], as well as 
variance component tests such as the C-alpha test [Neale, et al. 2011] and sequence kernel 
association test (SKAT) [Lee, et al. 2012; Wu, et al. 2011].
A notable caveat for these omnibus tests is that they do not provide any inference at the 
marker level as to which RVs may be driving a given multi-marker association. An 
alternative strategy is to simultaneously assess all of the RVs under consideration and apply 
some form of variable selection. One approach to identifying these RVs is to apply Bayesian 
variable selection procedures (for review, see [O'Hara and Sillanpaa 2009]). Use of these 
methods in marker association studies have the potential to be more powerful than other 
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model selection procedures [Quintana and Conti 2013; Wilson, et al. 2010], and additionally 
provide relevant posterior quantities of interest for variable inclusion. Recently, Bayesian 
model uncertainty (BMU) strategies have been proposed for RV association analysis in case-
control studies, referred to as the Bayesian risk index (BRI) [Quintana, et al. 2011]. The BRI 
method utilizes an aggregation and collapsing risk index parameterization of the selected 
RVs in a logistic regression framework, which we hereafter refer to as L-BRI. The authors' 
simulation results not only indicate increased power over traditional omnibus approaches for 
global association, but powerful detection of individual RVs driving an association signal 
through the derivation of marginal Bayes Factors (BFs).
A drawback of selecting the logit link function for the generalized linear model is that no 
closed-form solutions exist for the full conditional densities of the model parameters. 
Moreover, the Metropolis-Hastings (MH) algorithm for sampling from the model space in L-
BRI applies a single-component proposal procedure to the variable inclusion vector. This 
can result in a computationally intensive algorithm requiring many hours to run to fully 
explore the model space for higher RV counts, reserving practical applications to smaller 
regions of the genome. Recent findings from large-scale sequencing studies indicate that, 
from a population-based perspective, RV sites can be quite common [Nelson, et al. 2012]. 
Consequently, sufficient sample size and sequence content could yield a computationally 
burdensome quantity of RVs for the L-BRI method. An illustrative example of potentially 
high RV dimensionality is a targeted sequencing study of the DISC1 locus investigating 
association with psychiatric traits [Thomson, et al. 2013], which identified over 2000 
validated RVs (MAF < 1%) across the region of interest. Moreover, most sequencing studies 
are under-powered for gene-based analyses, prompting multi-genic analyses that aggregate 
rare variants across related genes in a given pathway[Wu and Zhi 2013]. Targeted analysis of 
multiple genes within a gene set could yield similarly extreme quantities of RVs. These 
applications may not be tenable for the L-BRI or similar approaches without application of 
strict exclusion criteria that could inadvertently filter out causal variation.
An alternative strategy to handling high dimensional rare variant analysis would be to apply 
Bayesian variable selection in a post-hoc fashion to identify potential causal variation 
driving an association finding from frequentist testing. One reformulation of the BRI 
approach would be to instead utilize the probit link function for the generalized linear model 
in combination with alternative MH algorithms that permit effective exploration of the 
model space. A key advantage of the Bayesian probit regression model is that closed forms 
of the full conditional distributions exist for appropriately selected conjugate priors using 
data augmentation techniques [Tanner and Wing 1987], resulting in efficient Gibbs 
sampling. The use of probit regression with Bayesian variable selection methods for high-
dimensional modeling has been demonstrated to be quite powerful in the analysis of gene 
expression [Baragatti 2011; Lee, et al. 2003; Leon-Novelo, et al. 2012; Yang and Song 
2010], capable of simultaneous consideration of hundreds to thousands of probesets. The 
utility of the probit regression approach relative to logistic regression for variant analysis in 
case-control sequencing studies was recently demonstrated by Kang et al. [Kang, et al. 
2014].
Larson et al. Page 3
Genet Epidemiol. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Here we propose a fully Bayesian probit regression BRI (P-BRI) method for detection of 
individual RV risk associations and define strategies for instances of high variant 
dimensionality. We outline the basic sampling algorithm, which is an adaptation of existing 
Bayesian variable selection procedures for probit regression. We then evaluate the power of 
our approach at detecting causal rare variants via simulation studies, detailing sensitivity and 
specificity under varying conditions against L-BRI, as well as apply P-BRI to high 
dimensional variant scenarios. To illustrate our method using real data, we apply our P-BRI 
approach to a prostate cancer (PC) case-control whole-exome sequencing (WES) analysis of 
the previously detected rare variant pathway associations. Finally, we discuss the advantages 
of our approach and outline extensions and future research directions.
Methods
Model definition
Consider a case-control rare variation association study with N subjects consisting of ND 
cases and NC controls, and let Y be an N × 1 vector of corresponding binary responses 
indicating affected status, such that Yi = 1 if the ith subject is a case and Yi = 0 if a control. 
Let Z be an N × p RV genotype matrix, where zij ≡ Z[i,j] represents the minor allele count 
for subject i at RV position j for j = 1, … p. We also define the N × q design matrix X 
consisting of q additional adjustment covariates, such as age or gender. In general, it is 
assumed that the proportion of truly causal RVs in Z is relatively small and that some form 
of model selection is desired to identify a subset of the total RVs that are associated with the 
trait of interest. For our approach we apply variable selection on the set of RVs in Z to 
characterize an RV load defined by the selected RVs. As such, each possible model ℳγ 
within the model space ℳ can be characterized through a variable inclusion vector γ, a p × 1 
vector of indicators such that γj = 1 denotes that the jth RV is included in the aggregation 
measure, yielding 2p total possible models. For even moderate values of p, enumeration of 
all 2p models ℳγ ∈ ℳ is not feasible.
To account for the effects of RVs on disease risk, we apply a risk index approach that 
considers the aggregate effect of multiple RVs by the collapsed measure , where Zi 
is a column vector corresponding to the ith row of Z. The scalar quantity zγ,i is the 
summation of minor alleles over the selected RVs in the model for subject i and indicates the 
subject-wise RV burden, and we denote Zγ = (zγ,1, …, zγ,N)′. We define the binary 
regression model, such that
where g(μ) is a link function and ηi denotes the linear predictor. For our approach, we select 
the probit link, such that g−1(μ) = Φ(μ), where Φ(μ) represents the standard Gaussian 
cumulative probability distribution function. The model likelihood can then be written as
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which does not initially provide analytical solutions for the model parameter posteriors. 
However, Albert and Chib [Albert and Chib 1993] proposed a data augmentation solution to 
computing probit regression posterior distributions by introducing the additional vector of 
independent latent variables Ỹ corresponding to Y, such that
and
where (μ,σ2) indicates a Gaussian distribution with mean μ and variance σ2. Thus, the 
observed dichotomous variable Y is indicative of the sign of the latent random variable Ỹ, 
which is modeled via linear regression with fixed variance.
Prior distributions
We opt for traditional conjugate priors where applicable in order to attain full conditional 
distributions. We first define the prior distribution on the vector of design covariate 
parameters, β, to be a q-dimensional multivariate Gaussian distribution such that
which is a conventional g-prior distribution [Zellner 1983] in probit regression coefficients 
for blocked Gibbs sampling. We similarly place a standard Gaussian prior on the BRI 
coefficient βγ, such that βγ ∼ (0,1).
We specify the prior probability of a given model ℳγ ∈ ℳ, Pr(ℳγ) through the individual 
variable prior inclusion probabilities Pr(γj = 1) = πj, such that 
. We define the model probability in this fashion via the 
assumption that the probabilities that given RVs are included in the model are independent, 
since low linkage disequilibrium is expected among RV sites [Pritchard 2001]. The vector π 
= (π1, …, πp)′ can either reflect no differential prior belief of inclusion, such that π1= ⋯ 
=πp= π, or may differ based upon available functional data that informs potential RV 
functionality in relation to the trait of interest. Similar to Quintana et al. [Quintana, et al. 
2011], we specify the default prior on γj to be , such that the prior 
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probability of the global null model  to account for 
the potential of a Type I error as well as render the models equitable in this regard.
Bayesian sampling algorithm
To obtain estimates of the posterior quantities of interest, we apply a Markov Chain Monte 
Carlo (MCMC) approach [Hastings 1970], whereby samples from the respective posterior 
distributions of the model parameters are iteratively drawn using Gibbs sampling (GS) and 
MH methods. To define our sampler, we first must characterize the full conditional 
distributions of the model parameters, which include f(Ỹ|Y,β,βγ,γ), f(β|Ỹ, βγ,γ), f(βγ|
Ỹ,β,γ), and f(γ|Ỹ,β,βγ,). The full conditional distributions for the first three can easily be 
derived, such that
•
 left truncated at 0
•
 right truncated at 0
•
 where 
•
 where 
Since these distributions are properly defined, GS methods can be used for iterative 
updating. However, under our BMU procedure, the full conditional distribution of γ cannot 
be directly simulated easily, requiring a Metropolis-within-Gibbs approach. To sample from 
the distribution of γ, we adopt a marginalization strategy [Liu 1994], which is based upon 
the integrated distribution of the full conditional of γ over βγ, f(γ|Ỹ,β). It can be shown 
using Bayesian linear model theory that f(γ|Ỹ,β) is proportional to
which we use to define a MH algorithm for updating γ, directly followed by simulation of 
βγ from its full conditional distribution.
There are a number of options for proposing new values of γ in the MH step of the MCMC 
sampler. Quintana et al. [Quintana, et al. 2011] elected a single-step addition/deletion MH 
algorithm for model selection in L-BRI, whereby the proposed vector γ is generated by 
switching the binary value of a randomly chosen variable inclusion indicator γj. However, in 
instances of higher RV dimensionality, this approach requires a prohibitively large number 
of iterations to adequately explore the model space ℳ, resulting in relatively poor mixing. In 
contrast, updating each γi in a component-wise fashion can significantly improve mixing 
and convergence and may result in overall better performance [Johnson, et al. 2013]. 
Consequently, we apply a component-wise multistep MH algorithm, similar to that applied 
by Lee et al.[Lee, et al. 2014] for imaging data, that iteratively updates each element in γ. 
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This is conducted in a modified metropolised Gibbs framework, such that the proposal for γi 
is always the opposite of the current state, yielding more efficient mixing[Liu 1996]. The 
unique formulation of the risk index as a product of a fixed design matrix Z and variable 
inclusion vector γ permits computationally efficient component-wise MH updating, which is 
generally infeasible for high dimensional problems. At each iteration of the MCMC 
algorithm we randomize the updating order of MH step for γ, and convergence to the 
stationary distribution may be checked by running multiple chains from different initial 
values and comparing posterior samples.
Given that the defined prior on the BRI parameter βγ has positive support over the entire 
real line, it is possible for the sampler to draw negative values of βγ despite it characterizing 
risk. One simple solution is to constrain the prior distribution to the positive real line by 
using a truncated normal prior. By Gelfand et al. [Gelfand, et al. 1992], we can 
accommodate this prior by adding a rejection step to the Gibbs sampler for βγ, accepting 
new draws of βγ, βγ(⋆), only if βγ(⋆) > 0.
Posterior measures of interest
Conditional on evidence against the global null model ℳ0 (e.g., from a previously conducted 
test), a primary motivation is identifying an interesting subset of variants associated with the 
disease of interest for follow-up analyses. In the case of variable selection problems, the 
marginal posterior probabilities of inclusion are useful for such inference. Denote ζj = 
Pr(γj=1|Y) to be the marginal posterior probability of inclusion for jth RV in Z. Quintana et 
al. [Quintana, et al. 2011] derive the marginal BFs to isolate RVs that may be driving an 
association, such that
We estimate ζj in a Monte Carlo fashion from the T posterior samples of γ, such 
. Decisions of relative importance of each RV can then be made with respect to 
common thresholds (e.g., >10 or 31.6) defined by Jeffreys' grades of evidence [Jeffreys 
1961] using these marginal BFs.
Simulations
To evaluate the performance of P-BRI at identifying individual risk associated RVs, we 
considered a hypothetical case-control genetic association study with N = 1000 total subjects 
(ND=NC). To simulate the RV genotype data conditional on disease status, we employed the 
model developed by Li and Leal [Li and Leal 2008] and algorithmically defined by Zhou et 
al. [Zhou, et al. 2010]. This model is based upon the conditional Poisson-binomial whereby 
any of the v risk RVs can independently cause the disease status, defined though the MAFs, 
prevalence, and relative risks of RVs. The MAFs for all RVs were randomly generated 
uniformly on the interval (0.005,0.01), and all simulated RVs that resulted in an empirical 
MAF of zero were excluded from analysis. Prevalence was fixed at 0.01 and no additional 
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covariates were included in the simulation model. Simulations under the null (i.e., no causal 
variation) simply involved random assignment of case-control status to randomly generated 
RV genotype vectors.
We first compared the performance of the P-BRI relative to the original L-BRI at detecting 
causal RVs in scenarios that were computationally reasonable for either method, fixing p = 
50. Software implementation of the L-BRI method is available via the R package BVS, 
which we applied under default settings unless otherwise noted. For simulations involving 
causal variation, we considered the quantity of truly causal RVs, v, to range from 5 to 15, 
and applied both the P-BRI and L-BRI methods to detect the associated RVs. All causal RVs 
were attributed a relative risk (RR) of 1.5, 2.5, or 5, with all remaining RVs being neutral 
(RR = 1). Convergence of the L-BRI was evaluated by running two parallel chains and 
comparing output marginal BFs, as per the method's documentation, with convergence 
defined by the root mean square error between the two sets of BFs to be < 1. To evaluate 
convergence of P-BRI, the Gelman-Rubin diagnostic was applied to MCMC posterior 
samples of βγ for two parallel chains with different starting values, with convergence 
declared if the upper 95% confidence limit was < 2. For the P-BRI method we sampled a 
total of 30,000 iterations, treating the first 15,000 as a burn-in, while for the L-BRI method 
we sampled 100,000 iterations and treated the first 50,000 as a burn-in. If convergence was 
not achieved at these iteration counts additional posterior samples were drawn until 
convergence criteria were met. Marginal BFs were also computed for P-BRI in order to 
compare the relative false positive (FPR) and true positive rates (TPR) based upon detection 
of causal variant status across all simulation iterations (50 × 500 = 25000 total variants). For 
P-BRI, instances where RVs had corresponding posterior inclusion probabilities (PIPs) 
estimates ζ̂j = 1 were adjusted to  to avoid division by zero in the marginal BF. For 
purposes of comparing performance between L-BRI and P-BRI relative to TPR and FPR, we 
computed bootstrapped 95% confidence intervals on these metrics and/or their differential 
across methods using the R package fbroc, based upon 1000 bootstrap samples.
To additionally examine the performance of P-BRI under high RV dimensionality, we 
increased the total RV counts to p = 500 and p = 1000 and fixed the number of true 
deleterious RVs to v = 25, such that the causal RV proportions were 5.0% (p = 500 and 2.5% 
(p = 1000), respectively. Given the larger quantity of RVs under simultaneous consideration, 
we focused on identification of larger effect sizes and examined performance for RRs of 2.5, 
5, and 10 for causal RVs. For these applications, the first 15,000 MCMC samples were 
discarded as a burn-in, resulting in a posterior sample size of 15,000.
Data Application: Prostate Cancer Risk
A whole-exome sequencing study of men with prostate cancer was conducted by the 
International Consortium of Prostate Cancer Genetics (ICPCG). The ICPCG has identified 
and sampled the most informative high-risk PC pedigrees known throughout the world. With 
the goal of identifying PC susceptibility loci utilizing this extraordinary collection of 
families, WES was performed on 539 familial cases of PC derived from 366 families all 
having at least three affected men with PC: 257 cases from 84 families (the majority having 
three sequenced/family) and 282 singleton cases. Whole-exome sequencing was performed 
Larson et al. Page 8
Genet Epidemiol. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
using the Agilent 50Mb SureSelect Human All Exon chip or the Agilent SureSelect 
V4+UTR kit. Bioinformatics analysis was performed using GenomeGPS, a comprehensive 
analysis pipeline developed at Mayo Clinic which performs alignment using Novoalign (v.
07.13), realignment and recalibration using the Genome Analysis Tool Kit (GATK,v3.3), 
germline single nucleotide and small insertion/deletion variant calling using GATK 
HaplotypeCaller, and Variant quality score recalibration (VQSR), following GATK best 
practices v3 [DePristo, et al. 2011; McKenna, et al. 2010; Van der Auwera, et al. 2013]. 
Population-based controls were selected from samples that were sequenced at Mayo Clinic 
using similar library preparation and sequencing to the cases. We identified 494 samples 
from four studies which met our inclusion criteria (germline sequencing using Agilent V2 or 
V4+UTR capture and with initial alignment performed using the same version of Novoalign. 
Samples included 89 unselected samples from the Mayo Clinic Community Biobank, 355 
samples from two studies of cardiovascular phenotypes and 50 samples from a study of 
neuropathy. All samples were re-processed using the bioinformatics pipeline described 
above and underwent the same stringent quality control analyses.
We conducted a pathway-directed RV case-control study (see Supplemental Methods for 
details) to evaluate the role of RVs in risk of PC using 860 gene-set definitions from KEGG 
[Kanehisa 2002] and Reactome [Joshi-Tope, et al. 2005]. For our purposes, we restricted our 
analyses to unrelated subjects by randomly selecting single individuals from pedigrees with 
multiple sequenced subjects. After sample exclusions for quality control or relatedness, a 
total of 333 cases and 349 controls remained. In our analyses, we identified multiple highly 
overlapping gene-sets related to the Lands cycle (Reactome IDs R-HSA-1482922.1, R-
HSA-1483226.1, R-HSA-1482788.1, R-HSA-1482839.1, R-HSA-1482925.1) to be 
significantly associated (P <5.8E-05) using SKAT-O[Lee, et al. 2012] and burden-based 
testing. The Lands cycle is involved in the acyl-chain remodeling of a variety of 
phospholipids, and the union of the associated pathways constitutes 26 genes involving 438 
unique observed variants with empirical MAF < 0.05. To investigate which RVs may be 
driving the association, we applied the P-BRI approach to the data, including additional 
covariate adjustment for WES capture kit and five leading principal components derived 
from the complete genetic data. Similar posterior sampling procedures that were used in the 
simulations were applied and no additional information was used to alter the priors on γ.
Results
Simulation Analysis
The TPRs for RV associations declared at a marginal BF threshold of BF ≥ 10 are presented 
in Table I. Overall, we observed higher TPR as well as FPRs for L-BRI relative to P-BRI, 
indicating marginal BFs to be larger in general for the L-BRI approach and rendering 
performance comparisons difficult. When evaluating TPRs at a fixed FPR of 0.01 (Table II), 
we noted comparable performance. We additionally observed reduced TPR at fixed RR 
effect sizes as the proportion of causal variants increased, regardless of method. This is 
likely due to the fact that models encompassing a larger number of causal variants are less 
likely under the default prior distribution on the model space ℳ. In general, performance 
was comparable between the two approaches, with P-BRI tending to perform better under 
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conditions of lower effect size and smaller proportion of causal variants and L-BRI under 
large effect sizes and higher causal variant proportion.
Marginal TPR and FPR results at BF thresholds of 10 and 31.6 for the high RV 
dimensionality simulations are presented in Table III. We observed similar patterns of 
performance with respect to underlying RR and causal variant proportions as observed in the 
low RV count simulations, with higher global TPRs for p = 500 relative to p = 1000 for a 
fixed causal variant effect size. Marginal RV detection evaluated by TPR and FPR was 
comparable across differing total number of evaluated variants at a fixed BF threshold, with 
increasing TPR at higher effect sizes with the FPR remaining relatively fixed.
The above simulation results do not take into account the likely high degree of multiple 
testing that would likely occur prior to post-hoc evaluation, as the simulations only consider 
the case where true causal variation is present. Consequently, false positive rates may be 
higher than reported, depending upon how Type I error was controlled at the first stage of 
testing. To evaluate the behavior of P-BRI under false positive testing results, we conducted 
an additional 500 simulations for each of the high variant dimensionality conditions where 
none of the simulated variants were associated with case/control status. At a BF threshold of 
10, variant-level false positive rates were commensurate with those reported in Table III 
(0.012 for p = 500; 0.013 for p = 1000).
Data Application
The marginal BFs for the 438 RVs analyzed in the PC risk analysis are presented in Figure 
1. A total of four variants in three separate genes corresponded to a BF >10 (Table IV), 
including a splice-site variant in gene PLA2G4F (hg19 chr15:42448635A→T) with a 
corresponding marginal BF of 2787.7 and PIP of 0.815, occurring in 19 cases but only one 
control. Both PLA2G4D and PLA2G4F encode proteins that selectively hydrolyze 
glycerophospholipids, and dysregulation of lipid metabolism has been noted in many 
cancers[Huang and Freter 2015].
To evaluate the MCMC mixing for the data application, we computed the model mutation 
rate as the proportion of posterior samples that resulted in model state transitions (77.5%). 
Computational runtime for the full 30,000 iterations was approximately 20 minutes. Similar 
application of L-BRI resulted in only 188 accepted model transitions (mutation rate = 
1.25%) for the same number of iterations. After 100,000 iterations (∼1 hour runtime) for 
two independent runs with a 50,000 burn-in, examination of the marginal BF output from L-
BRI still indicated lack of convergence.
Discussion
In this paper, we have presented a regression-based Bayesian variable selection strategy for 
post-hoc analysis of aggregative RV associations in disease risk via a reformulation of the 
BRI method for case-control RV association analysis. By modeling the probability of 
affected status using a probit link function, in contrast to a logistic regression approach, we 
have demonstrated the method to be feasible for high dimensional applications. We have 
also proposed a component-wise MH algorithm for updating the variable inclusion vector γ, 
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which results in rapid exploration of the model space. Our simulation results comparing L-
BRI and P-BRI for moderate RV counts indicate that their ability to detect causal RVs is 
comparable for a variety of conditions, while P-BRI was also capable of detecting causal 
variation under very high RV dimensionality. This renders P-BRI a powerful method for 
dense post-hoc RV association analyses, as evidenced by both our large-scale simulations 
and our PC risk analysis of 438 RVs within genes involved in the Lands Cycle. The 
application of our approach indicates the significant associations previously detected by 
pathway-based analyses may be driven by variants within three phospholipase genes and 
additional targeted sequencing of these genes may be warranted in future research.
From a computational perspective, our probit approach benefits from a multi-step MH 
algorithm for updating variable inclusion vector γ. Execution runtimes for P-BRI in our 
simulation study under conditions where p = 50 and N = 1000 averaged 6.2 minutes, while 
runtimes for our larger simulations where p = 1000 and N = 1000 at 30,000 iterations were 
approximately 75 minutes on average. The latter analyses were not feasible for L-BRI in our 
simulations due to the high model space dimensionality and single-step updating of γ. These 
timings are based upon working code written in the R statistical language and executed on a 
modern workstation equipped with a Quad-Core AMD Opteron™ Processor and 16 Gb of 
RAM. We anticipate that computational burden for the P-BRI method may be further 
reduced substantially with alternative BVS methods, such as objective Bayes model 
selection [Leon-Novelo, et al. 2012] and particle stochastic search [Shi and Dunson 2011] 
approaches, as well as implementation of parts of the current MCMC algorithm in more 
computationally efficient computer languages such as C++.
A simplifying assumption of risk index methods in general is that each included RV 
contributes an equal effect to the RV burden, or rather that it models the mean effect of the 
selected RVs. While this assumption permits efficient sampling, it may not accurately reflect 
the effects of the individual RV associations. It is possible to utilize existing structural 
definitions, such as genes or exons, as a grouping mechanism and assign separate burden-
based parameters, although careful consideration is necessary to avoid singular design 
matrices if the number of included elements exceeds the sample size. If protective RV's are 
present, they would not be appropriately modeled by our approach. However, the P-BRI 
method could be simply modified by increasing the support of γ to include negative 
indicators, as in the MixBRI approach by Quintana et al. [Quintana, et al. 2011].
Although the P-BRI method permits efficient exploration of high-dimensional model spaces, 
alternative MH algorithms for sampling from the model space ℳ may be useful in extreme 
scenarios where the RV dimensionality renders the component-wise MH algorithm 
computationally infeasible. One approach is to consider a subset of the model space ℳ, ℳb, 
by defining the MH transition kernel such that the number of included RVs in any model ℳγ 
∈ ℳb is invariant and equal to an a priori defined quantity b. This approach is comparable to 
the MCMC algorithm outlined in Baragatti [Baragatti 2011] and preliminary simulations 
indicate feasibility for P-BRI with p ≥ 10,000, although further work is necessary to 
formally develop these methods. Adaptive algorithms designed for high-dimensional 
sampling in GWAS may also be of utility[Peltola, et al. 2012].
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There are a variety of promising extensions from our development of the P-BRI method for 
post-hoc RV analysis. An added benefit of this work is that application to quantitative traits 
is trivial, since the algorithms are already in place through the latent variable Ỹ, although 
variational Bayesian methods have previously demonstrated high computational efficiency 
in this area[Logsdon, et al. 2014]. We could also extend the regression procedure to include 
common variants in the model selection for a comprehensive association analysis, as well as 
easily adopt the integrative variable selection procedures in Quintana et al. [Quintana and 
Conti 2013] for informed model selection based upon existing variant annotation. Finally, 
we are actively evaluating methods to estimate global null model posterior probabilities 
using sampling procedures implemented by Liang et al.[Liang and Xiong 2013] for 
association inference, as well as integrating P-BRI methods with curated pathway databases 
to facilitate genome-wide exploratory rare variant gene-set analysis.
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Figure 1. 
Depiction of BFs (y-axis on log10 scale) for all 438 RVs within 26 genes related to 
pathways previously identified to have significant associations with PC risk in the data set. 
Colors of the points alternate by gene membership from dark gray to light gray, and the y-
axis is annotated in the original scale. Horizontal lines depict BF thresholds of 10 and 31.6.
Larson et al. Page 15
Genet Epidemiol. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Larson et al. Page 16
Ta
bl
e 
I
Si
m
ul
at
io
n 
re
su
lts
 fo
r e
m
pi
ric
al
 T
PR
s a
nd
 F
PR
s a
nd
 c
or
re
sp
on
di
ng
 b
oo
tst
ra
pp
ed
 9
5%
 co
nf
id
en
ce
 in
te
rv
al
s f
or
 c
au
sa
l R
V
 d
et
ec
tio
n 
ac
ro
ss
 si
m
ul
at
io
n 
re
pl
ic
at
io
ns
 w
ith
 fi
xe
d 
m
ar
gi
na
l B
F 
th
re
sh
ol
d 
se
t t
o 
10
 (“
str
on
g”
 ev
id
en
ce
).
ν =
5
ν =
10
ν =
15
M
et
ho
d
R
R
TP
R
FP
R
TP
R
FP
R
TP
R
FP
R
P-
B
R
I
1.
5
0.
34
1 
(0.
32
3,0
.36
0)
0.
01
2 
(0.
01
1,0
.01
4)
0.
33
1 
(0.
31
7,0
.34
4)
0.
01
4 
(0.
01
3,0
.01
6)
0.
31
3 
(0.
30
3,0
.32
4)
0.
01
5 
(0.
01
3,0
01
6)
L-
B
R
I
0.
31
4 
(0.
29
5,0
.33
3)
0.
01
7 
(0.
01
5,0
.01
9)
0.
40
5 
(0.
39
1,0
.41
7)
0.
03
0 
(0.
02
8,0
.03
3)
0.
43
4 
(0.
42
3,0
.44
5)
0.
03
9 
(0.
03
6,0
.04
2)
P-
B
R
I
2.
5
0.
69
4 
(0.
67
7,0
.71
3)
0.
01
4 
(0.
01
2,0
.01
5)
0.
64
3 
(0.
63
0,0
.65
6)
0.
01
4 
(0.
01
3,0
.01
6)
0.
56
9 
(0.
55
8,0
.58
1)
0.
01
4 
(0.
01
2,0
01
6)
L-
B
R
I
0.
76
1 
(0.
74
6,0
.77
9)
0.
03
5 
(0.
03
3,0
.03
8)
0.
80
6 
(0.
79
6,0
.81
7)
0.
05
8 
(0.
05
5,0
.06
1)
0.
78
4 
(0.
77
4,0
.79
3)
0.
07
0 
(0.
06
7,0
.07
4)
P-
B
R
I
5.
0
0.
97
2 
(0.
96
6,0
.97
8)
0.
01
3 
(0.
01
2,0
.01
5)
0.
92
9 
(0.
92
3,0
,93
6)
0.
01
4 
(0.
01
3,0
.01
6)
0.
86
7 
(0.
85
9,0
.87
5)
0.
01
4 
(0.
01
3,0
01
6)
L-
B
R
I
0.
98
6 
(0.
98
1,0
.99
0)
0.
03
9 
(0.
03
6,0
.04
1)
0.
97
8 
(0.
97
4,0
.98
2)
0.
06
1 
(0.
05
8,0
.06
4)
0.
96
5 
(0.
96
1,0
.96
9)
0.
09
0 
(0.
08
6,0
.09
5)
Genet Epidemiol. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Larson et al. Page 17
Table II
Simulation results for empirical TPRs for causal RV detection across simulation replications at a fixed FPR of 
0.01. For comparisons across methods, the difference in TPR (Δ) and corresponding bootstrap 95% confidence 
interval are reported.
True Positive Rate
Method RR ν =5 ν =10 ν =15
P-BRI 1.5 0.324 0.288 0.265
L-BRI 0.253 0.262 0.250
 Δ (95% CI) 0.070 (0.056,0.086) 0.026 (0.012,0.038) 0.015 (0.002,0.027)
P-BRI 2.5 0.660 0.603 0.523
L-BRI 0.638 0.612 0.560
  Δ (95% CI) 0.022 (0.014,0.034) -0.009 (-0.020,0.001) -0.037 (-0.049,-0.022)
P-BRI 5.0 0.966 0.919 0.845
L-BRI 0.968 0.929 0.877
  Δ (95% CI) -0.002 (-0.006,0.001) -0.010 (-0.015,-0.007) -0.032 (-0.039,-0.024)
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Table III
Simulation results for P-BRI in high RV dimensionality (p = 500, 1000) for marginal TPR and FPRs at 
traditional BF thresholds (10 and 31.6), along with bootstrap 95% confidence intervals.
Marginal (BF>10) Marginal (BF>31.6)
RR TPR FPR TPR FPR
p =500
2.5 0.379 (0.368,0.385) 0.014 (0.014,0.015) 0.235 (0.228,0.241) 0.004 (0.004,0.004)
5.0 0.605 (0.596,0.613) 0.014 (0.013,0.014) 0.477 (0.468,0.486) 0.004 (0.004,0.004)
10.0 0.833 (0.826,0.840) 0.012 (0.012,0.013) 0.762 (0.754,0.770) 0.004 (0.004,0.004)
p =1000
2.5 0.378 (0.369,0.386) 0.013 (0.013,0.014) 0.238 (0.231,0.245) 0.004 (0.003,0.004)
5.0 0.586 (0.577,0.594) 0.014 (0.014,0.014) 0.454 (0.445,0.461) 0.004 (0.004,0.004)
10.0 0.801 (0.794,0.808) 0.013 (0.012,0.013) 0.717 (0.709,0.725) 0.004 (0.004,0.004)
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